Leiomyosarcoma of the stomach: A case report

Kang, Wenzhe; Xue, Li-Yan; Tian, Yantao

doi:10.12998/wjcc.v7.i21.3558

Cited by 1 publication

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The genes revealed in the panel included KIT, PDGFRA, SDHA, SDHB, SDHC, SDHD, BRAF, KRAS, NRAS, and EGFR, without mutations in any of them. The patient died with gastrointestinal obstruction and malnutrition one year after surgery [4]. Mehta et al described a 47-year-old male two years after the diagnosis of a huge gastric LMS (130 mm x 130 mm x 100 mm) in the greater curvature, and then excised by laparotomy [6].…”

Section: Discussionmentioning

confidence: 99%

“…Leiomyosarcoma (LMS) represents about 1% of primary malignancies of the stomach, evolves with hepatic implants in 2-thirds of cases, and the outcome is often poor [1][2][3][4][5][6][7]. Immunosuppression, Epstein-Barr virus, chemicals, and radiation can be related factors [2,6].…”

Section: Introductionmentioning

confidence: 99%

“…Spindle cells of the muscularis propria or muscularis mucosa present high proliferation rates and positivity for desmin, a-muscle-specific actin, and vimentin [2,3,6]. Although immunohistochemical findings can avoid pitfalls with other gastrointestinal tumors, the diagnosis often occurs at late stages because of the insidious clinical course [2][3][4][5][6][7]. LMS predominantly affects female adults (5:3) and the sixth decade of life, pain occurs in near 75% of patients and the control is very difficult in most of them [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…LMS predominantly affects female adults (5:3) and the sixth decade of life, pain occurs in near 75% of patients and the control is very difficult in most of them [1,2]. Bleeding, weight loss, and gastroesophageal reflux are other frequent symptoms [2][3][4]. Whenever possible, surgical resection is the effective treatment; otherwise, palliative care and repeated hepatectomy for metastasis resection may prolong the survival rate in some cases [1][2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

“…Bleeding, weight loss, and gastroesophageal reflux are other frequent symptoms [2][3][4]. Whenever possible, surgical resection is the effective treatment; otherwise, palliative care and repeated hepatectomy for metastasis resection may prolong the survival rate in some cases [1][2][3][4][5]. Recurrences after resections and distant metastases may develop in up to 50% of patients [5].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Metastatic leiomyosarcoma of the excluded stomach: a case report

Silva

Santos

Santos³

2020

Journal of Gastric Surgery

View full text Add to dashboard Cite

Background: Leiomyosarcoma (LMS) represents about 1% of primary malignancies of the stomach, usually evolves with hepatic implants in 2-thirds of cases, and the outcome is frequently poor. With an insidious course, late diagnosis and misdiagnosis with other gastric neoplasia occur. Immunohistochemical evaluations are mandatory to confirm the diagnostic hypothesis. Surgical resection has been the more effective treatment of gastric LMS; however, recurrences after resections and distant metastases may develop in up to 50% of the patients. Doxorubicin, gemcitabine, and docetaxel are therapeutic options, with variable responses. Case presentation: The 52-year-old male herein described with a diagnosis of LMS in the gastric pouch and liver metastasis underwent a Roux-en-Y bypass to treat morbid obesity more than a decade ago. Persistent abdominal pain was a unique symptom, and he had liver metastasis at diagnosis. The initial hypothesis was a metastatic gastrointestinal stromal tumor (GIST) of the excluded stomach and the patient underwent a schedule with imatinib without significant response. After a complete revision of the anatomopathological findings, the patient underwent a new biopsy of the gastric mass, and the immunohistochemical data were consistent with LMS. Then doxorubicin replaced imatinib, later changed by gemcitabine associated with docetaxel. As last control found lesions in the central nervous system, he is under radiotherapy sessions. Conclusion: The diagnosis of gastric LMS often occurs at late stages because of the insidious clinical course. The rate of liver metastasis at diagnosis is high. Besides, the relatively poor response to the alternative management for non-surgical stages of the disease yields severe outcomes.

show abstract

Section: Discussionmentioning

confidence: 99%